Published in J Med Chem on March 12, 1998
Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. J Med Chem (2010) 2.12
Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest (2002) 1.62
Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol (1999) 1.01
The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay. Br J Pharmacol (1999) 0.95
Phosphodiesterase 4-targeted treatments for autoimmune diseases. BMC Med (2013) 0.88
Role of PDE4 in superoxide anion generation through p44/42MAPK regulation: a cAMP and a PKA-independent mechanism. Br J Pharmacol (2004) 0.84
ABCD of the phosphodiesterase family: interaction and differential activity in COPD. Int J Chron Obstruct Pulmon Dis (2008) 0.84
Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors. Bioorg Med Chem Lett (2014) 0.84
Treating COPD with PDE 4 inhibitors. Int J Chron Obstruct Pulmon Dis (2007) 0.83
Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors. J Med Chem (2008) 0.82
Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). Biochem Pharmacol (2013) 0.79
CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities. Br J Pharmacol (2005) 0.76
Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J Gen Virol (2001) 4.25
The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J Gen Virol (2001) 3.95
Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther (1996) 2.63
Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem (1998) 2.32
Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem (2000) 2.24
Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology (2000) 2.12
Pharmacological regulation of calmodulin. Ann N Y Acad Sci (1980) 2.02
Inflammatory mediators of experimental colitis in rats. Gastroenterology (1989) 2.01
A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor [see commetns]. Science (1998) 1.86
The cleavage activities of aphthovirus and cardiovirus 2A proteins. J Gen Virol (1997) 1.82
Assessment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods (1990) 1.79
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol (2000) 1.75
Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum (2000) 1.72
Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc (1972) 1.69
Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. Mol Pharmacol (1990) 1.67
Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus. J Antimicrob Chemother (2001) 1.61
Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem (1989) 1.57
Methylprednisolone in the management of acute spinal cord injuries. Med J Aust (1990) 1.53
Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J Immunol (2001) 1.47
Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther (1998) 1.46
Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase. Mol Cell Biol (1990) 1.45
Polymorphonuclear leukocyte infiltration into cerebral focal ischemic tissue: myeloperoxidase activity assay and histologic verification. J Neurosci Res (1991) 1.45
Depo-Medrol and myelographic arachnoiditis. Med J Aust (1991) 1.43
Extrapulmonary tuberculosis in children. Med J Aust (1993) 1.38
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther (2000) 1.37
Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. J Biol Chem (2000) 1.34
Self-processing 2A-polyproteins--a system for co-ordinate expression of multiple proteins in transgenic plants. Plant J (1999) 1.31
Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg Med Chem (1997) 1.31
Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exp Ther (2001) 1.31
A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA. J Biol Chem (1993) 1.26
Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists. J Immunol (1984) 1.25
Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci (1995) 1.23
Synthesis of foot-and-mouth disease virus capsid proteins in insect cells using baculovirus expression vectors. J Gen Virol (1990) 1.23
The structure of ribonuclease P protein from Staphylococcus aureus reveals a unique binding site for single-stranded RNA. J Mol Biol (2000) 1.21
Enabling technologies for manipulating multiple genes on complex pathways. Plant Mol Biol (2001) 1.20
Potent and selective nonpeptide inhibitors of caspases 3 and 7. J Med Chem (2001) 1.18
Foot-and-mouth disease virus particles contain replicase protein 3D. Proc Natl Acad Sci U S A (1994) 1.18
Staurosporine-induced apoptosis in cardiomyocytes: A potential role of caspase-3. J Mol Cell Cardiol (1998) 1.17
Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther (1999) 1.17
Structure determination of racemic trichogin A IV using centrosymmetric crystals. Nat Struct Biol (1994) 1.17
Direct cleavage of the human DNA fragmentation factor-45 by granzyme B induces caspase-activated DNase release and DNA fragmentation. EMBO J (2001) 1.17
Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun (1997) 1.16
Inhibition of the low km cyclic AMP phosphodiesterase in intact canine trachealis by SK&F 94836: mechanical and biochemical responses. J Pharmacol Exp Ther (1988) 1.15
Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J Biol Chem (1992) 1.15
Lower esophageal sphincter relaxation is associated with increased cyclic nucleotide content. Am J Physiol (1986) 1.14
1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI). Bioorg Med Chem Lett (2001) 1.14
Neurological deterioration after reduction of cervical subluxation. Mechanical compression by disc tissue. J Bone Joint Surg Br (1992) 1.11
Design of potent and selective human cathepsin K inhibitors that span the active site. Proc Natl Acad Sci U S A (1997) 1.10
Susceptibility to ozone-induced airway inflammation is associated with decreased levels of surfactant protein D. Respir Res (2006) 1.10
Functional antagonism in canine tracheal smooth muscle: inhibition by methacholine of the mechanical and biochemical responses to isoproterenol. J Pharmacol Exp Ther (1983) 1.10
In vitro and in vivo mechanisms of leukotriene-mediated bronchoconstriction in the guinea pig. J Pharmacol Exp Ther (1982) 1.10
Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J Pharmacol Exp Ther (1994) 1.10
Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J Pharmacol Exp Ther (1993) 1.09
Differentiating infection from vaccination in foot-and-mouth disease using a panel of recombinant, non-structural proteins in ELISA. Vaccine (1998) 1.08
In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res (1989) 1.08
Inhibitory effect of methacholine on drug-induced relaxation, cyclic AMP accumulation, and cyclic AMP-dependent protein kinase activation in canine tracheal smooth muscle. J Pharmacol Exp Ther (1985) 1.07
Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg Med Chem Lett (1998) 1.07
Odontoid fractures. A rational approach to treatment. J Bone Joint Surg Br (1982) 1.07
Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J Pharmacol Exp Ther (1993) 1.06
Studies on the active site of succinyl-CoA:tetrahydrodipicolinate N-succinyltransferase. Characterization using analogs of tetrahydrodipicolinate. J Biol Chem (1986) 1.06
Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity. Bioorg Med Chem Lett (2001) 1.05
Distraction fractures of the lumbar spine. J Bone Joint Surg Br (1982) 1.05
Intracellular expression and processing of foot-and-mouth disease virus capsid precursors using vaccinia virus vectors: influence of the L protease. Virology (1990) 1.05
Inhibition of caspase-3-like activity prevents apoptosis while retaining functionality of human chondrocytes in vitro. J Orthop Res (2000) 1.03
Cyclic nucleotide-dependent protein kinases in airway smooth muscle. J Biol Chem (1982) 1.02
Thoracic adolescent idiopathic scoliosis: perinatal and environmental aspects in a Swedish population and their relationship to curve severity. J Pediatr Orthop (1987) 1.02
Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth-muscle cells. Modulation by cyclic adenosine monophosphate. Am J Respir Cell Mol Biol (2000) 1.02
Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors. Ann N Y Acad Sci (1993) 1.01
Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol (1999) 1.01
Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. Inflammation (1993) 1.01
New roles for structure in biology and drug discovery. Nat Struct Biol (2000) 1.01
SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther (1998) 1.01